U.S. Building Stock News

NasdaqGS:PYXS
NasdaqGS:PYXSBiotechs

Creative Global Technology Holdings And 2 Other Promising Penny Stocks

Over the last 7 days, the U.S. market has risen by 2.6%, and in the past year, it has climbed an impressive 26%, with earnings forecasted to grow by 17% annually. In such a robust market environment, identifying stocks with solid financials becomes crucial for investors seeking potential growth opportunities. Though often considered a relic of past trading days, penny stocks still hold relevance today as they offer affordability and growth potential when backed by strong fundamentals; this...
NYSE:LXU
NYSE:LXUChemicals

Uncovering US Hidden Gems with Promising Potential

The United States market has shown a robust performance, rising by 2.6% over the last week and climbing 26% in the past year, with earnings projected to grow by 17% annually. In this dynamic environment, identifying stocks that offer strong fundamentals and unique growth opportunities can be key to uncovering hidden gems with promising potential.
NYSE:INGR
NYSE:INGRFood

3 Dividend Stocks To Consider With Up To 9.8% Yield

The United States market has shown robust performance recently, climbing 2.6% in the last week and 26% over the past year, with earnings forecasted to grow by 17% annually. In such a dynamic environment, selecting dividend stocks with attractive yields can be a strategic way to generate income while potentially benefiting from overall market growth.
NasdaqGS:OLPX
NasdaqGS:OLPXPersonal Products

Olaplex (OLPX) Q1 Loss Per Share Rekindles Debate Around Turnaround Narratives

Olaplex Holdings (OLPX) opened Q1 2026 with revenue of US$99.4 million and a basic EPS loss of US$0.01, while trailing 12 month figures show revenue of US$425.4 million and a basic EPS loss of US$0.02, keeping the company in loss making territory. Over recent quarters, revenue has moved between US$96.98 million and US$114.6 million with EPS swinging from a profit of US$0.02 in Q3 2025 to losses in several periods, highlighting how sensitive margins remain as the business works through its...
NasdaqGS:NTRA
NasdaqGS:NTRABiotechs

Why Natera (NTRA) Is Down 5.9% After Raising 2026 Guidance But Posting a Wider Q1 Loss

Natera, Inc. reported past first-quarter 2026 results with revenue rising to US$696.64 million from US$501.83 million a year earlier, while net loss widened to US$85.09 million and basic loss per share from continuing operations increased to US$0.60. The company delivered record testing volumes, raised its 2026 revenue and gross margin guidance, yet reported a larger loss as operating expenses for clinical trials, new products and international expansion increased. We’ll now examine how...
NYSE:BMI
NYSE:BMIElectronic

Assessing Badger Meter (BMI) Valuation After A Sharp Pullback And Mixed Intrinsic Value Signals

Recent performance and valuation signals Badger Meter (BMI) has drawn fresh attention after a sustained share pullback, with the stock down about 25% over the past month and about 24% over the past 3 months from its recent levels. At a last close of US$116.67 and an indicated intrinsic discount of about 5%, investors are reassessing how the company’s water metering and flow instrumentation business aligns with their expectations and risk tolerance. See our latest analysis for Badger...
NYSE:LMND
NYSE:LMNDInsurance

Should Lemonade’s (LMND) New State Rollout Redefine Its AI-Driven Insurance Scale Ambitions?

Lemonade has recently launched its award-winning, fully digital renters insurance in Delaware, New Hampshire, and West Virginia, offering flexible coverage starting from US$5 per month with instant app-based quoting and claims handling. By extending renters coverage to these additional states and now serving a large share of the U.S. population, Lemonade is broadening its addressable market while showcasing its AI-driven, low-cost operating model. We’ll now examine how Lemonade’s rapid...
NasdaqGM:AXSM
NasdaqGM:AXSMPharmaceuticals

Axsome’s AUVELITY Alzheimer’s Approval Sparks Valuation And Growth Questions

Axsome Therapeutics (NasdaqGM:AXSM) received U.S. FDA approval for AUVELITY for agitation associated with dementia due to Alzheimer’s disease. AUVELITY becomes the first approved treatment in this indication, addressing a major unmet medical need. The decision introduces a new commercial opportunity for Axsome in neuropsychiatric disorders. Axsome’s AUVELITY approval comes with the stock at $216.47 and follows very large 3 year and 5 year share price gains, alongside a 96.5% return over the...
NYSE:BG
NYSE:BGFood

How Surging Sales But Weaker Margins At Bunge Global (BG) Has Changed Its Investment Story

Bunge Global SA reported past first-quarter 2026 results, with sales rising to US$21.86 billion from US$11.64 billion a year earlier, while net income fell to US$68 million from US$201 million and diluted EPS from continuing operations declined to US$0.35 from US$1.48. This combination of very large revenue growth alongside weaker profitability highlights how cost pressures, mix shifts, or integration effects can materially affect the company’s earnings power despite higher volumes. We’ll...